Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers

Tracer‐specific reference tissues selection improves detection of 18 F‐FDG , 18 F ‐florbetapir, and 18 F ‐flortaucipir PET SUVR changes in Alzheimer's disease

(2022) Yanxiao Li et al.   HUMAN BRAIN MAPPING

Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans

(2021) Sohee Moon et al.   Alzheimers Research & Therapy

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease

(2021) Pratishtha Chatterjee et al.   Translational Psychiatry

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study

(2021) Adam M. Brickman et al.   Alzheimers & Dementia

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers

(2021) N. J. Ashton et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Profiling of Serum Exosome MiRNA Reveals the Potential of a MiRNA Panel as Diagnostic Biomarker for Alzheimer’s Disease

(2021) Zhiwu Dong et al.   MOLECULAR NEUROBIOLOGY

The Diagnostic Value of Exosome-Derived Biomarkers in Alzheimer's Disease and Mild Cognitive Impairment: A Meta-Analysis

(2021) Wenmin Xing et al.   Frontiers in Aging Neuroscience

Assessment of the Concordance and Diagnostic Accuracy Between Elecsys and Lumipulse Fully Automated Platforms and Innotest

(2021) Farida Dakterzada et al.   Frontiers in Aging Neuroscience

The PrecivityAD™ Test: Accurate and Reliable LC-MS/MS Assays for Quantifying Plasma Amyloid Beta 40 and 42 and Apolipoprotein E Proteotype for the Assessment of Brain Amyloidosis

(2021) Kristopher M. Kirmess et al.   CLINICA CHIMICA ACTA

A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

(2021) Tim West et al.   Molecular Neurodegeneration

Pathological drivers of neurodegeneration in suspected non-Alzheimer’s disease pathophysiology

(2021) L. E. M. Wisse et al.   Alzheimers Research & Therapy

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects

(2021) Joana B Pereira et al.   BRAIN

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease

(2021) Joana B Pereira et al.   BRAIN

Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease

(2021) D. O. T. Alawode et al.   JOURNAL OF INTERNAL MEDICINE

Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study

(2021) Anne M Fagan et al.   LANCET NEUROLOGY

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study

(2021) Elisabeth H Thijssen et al.   LANCET NEUROLOGY

Biomarkers for neurodegenerative diseases

(2021) Oskar Hansson   NATURE MEDICINE

Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status

(2021) Rosha Babapour Mofrad et al.   Alzheimers Research & Therapy

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

(2021) Constance Delaby et al.   Alzheimers & Dementia

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation

(2021) Charlotte E Teunissen et al.   LANCET NEUROLOGY

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques

(2021) Yan Li et al.   NEUROLOGY

Detection of increased serum miR-122-5p and miR-455-3p levels before the clinical diagnosis of liver cancer in people with type 2 diabetes

(2021) Heung Man Lee et al.   Scientific Reports

Identification of Circulating Exosomal miR-101 and miR-125b Panel Act as a Potential Biomarker for Hepatocellular Carcinoma

(2021) Li Sun et al.   International Journal of Genomics

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status

(2021) Xue-Ning Shen et al.   Translational Psychiatry

Neurofilaments: neurobiological foundations for biomarker applications

(2020) Arie R Gafson et al.   BRAIN

Total Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis

(2020) James D. Doecke et al.   NEUROLOGY

Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis

(2020) Luisa Agnello et al.   SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

(2020) Sebastian Palmqvist et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   BRAIN

Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology

(2020) Inge M. W. Verberk et al.   Alzheimers Research & Therapy

ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration

(2020) Katheryn A.Q. Cousins et al.   Alzheimers & Dementia

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

(2020) Shorena Janelidze et al.   JAMA Neurology

Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment

(2019) Patrick Oeckl et al.   JOURNAL OF ALZHEIMERS DISEASE

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease

(2019) Oliver Preische et al.   NATURE MEDICINE

Astrocyte Biomarkers in Alzheimer’s Disease

(2019) Stephen F. Carter et al.   TRENDS IN MOLECULAR MEDICINE

Blood-based molecular biomarkers for Alzheimer’s disease

(2019) Henrik Zetterberg et al.   Molecular Brain

Glial activation and inflammation along the Alzheimer’s disease continuum

(2019) Kaja Nordengen et al.   Journal of Neuroinflammation

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease

(2019) Andrea Vergallo et al.   Alzheimers & Dementia

Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid

(2019) Valeria Lifke et al.   CLINICAL BIOCHEMISTRY

Extracellular Vesicle as a Source of Alzheimer’s Biomarkers: Opportunities and Challenges

(2019) Seongju Lee et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Altered microRNAs related to synaptic function as potential plasma biomarkers for Alzheimer’s disease

(2019) Dolores Siedlecki-Wullich et al.   Alzheimers Research & Therapy

Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease

(2019) Niklas Mattsson et al.   JAMA Neurology

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

(2019) Suzanne E. Schindler et al.   NEUROLOGY

Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid

(2019) Petros Takousis et al.   Alzheimers & Dementia

Blood circulating miRNAs as biomarkers of Alzheimer’s disease: a systematic review and meta-analysis

(2019) Ya-Heng Zhang et al.   Biomarkers in Medicine

The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer′s Disease (AD)

(2019) Mroczko et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Systematic assessment of commercially available low-input miRNA library preparation kits

(2019) Fatima Heinicke et al.   RNA Biology

Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer’s disease

(2019) Michael Ewers et al.   Science Translational Medicine

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease

(2019) Maria João Leitão et al.   Alzheimers Research & Therapy

Cerebrospinal fluid progranulin is associated with increased cortical thickness in early stages of Alzheimer's disease

(2019) Lucia Batzu et al.   NEUROBIOLOGY OF AGING

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays

(2019) Kaj Blennow et al.   Scientific Reports

Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study

(2019) Virginia Pérez-Grijalba et al.   Alzheimers Research & Therapy

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

(2018) Michelle M. Mielke et al.   Alzheimers & Dementia

The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable

(2018) David S. Knopman et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer’s Disease

(2018) Henrik Zetterberg et al.   JOURNAL OF ALZHEIMERS DISEASE

Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment

(2018) Inês Baldeiras et al.   Alzheimers Research & Therapy

Cerebrospinal Fluid Level of YKL-40 Protein in Preclinical and Prodromal Alzheimer's Disease

(2018) Anna Antonell et al.   JOURNAL OF ALZHEIMERS DISEASE

Implementation of [18F]-labeled amyloid brain PET imaging biomarker in the diagnosis of Alzheimer’s disease

(2018) Tanyaluck Thientunyakit et al.   NUCLEAR MEDICINE COMMUNICATIONS

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease

(2018) Piotr Lewczuk et al.   Alzheimers Research & Therapy

Serum Soluble Triggering Receptor Expressed on Myeloid Cells 2 as a Biomarker for Incident Dementia: The Hisayama Study

(2018) Tomoyuki Ohara et al.   ANNALS OF NEUROLOGY

Blood-based biomarkers for Alzheimer’s disease—An update

(2018) Henrik Zetterberg   JOURNAL OF NEUROSCIENCE METHODS

Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic

(2018) Harald Hampel et al.   Nature Reviews Neurology

CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum

(2018) Boris-Stephan Rauchmann et al.   NEUROBIOLOGY OF AGING

MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer’s disease

(2017) Subodh Kumar et al.   HUMAN MOLECULAR GENETICS

Microglia in Alzheimer’s disease

(2017) David V. Hansen et al.   JOURNAL OF CELL BIOLOGY

Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

(2017) Harutsugu Tatebe et al.   Molecular Neurodegeneration

Review: Tau in biofluids - relation to pathology, imaging and clinical features

(2017) H. Zetterberg   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer’s disease patients from non-demented subjects

(2017) Siranjeevi Nagaraj et al.   Oncotarget

Lipidomic and Transcriptomic Basis of Lysosomal Dysfunction in Progranulin Deficiency

(2017) Bret M. Evers et al.   Cell Reports

Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer’s disease

(2017) Norikazu Hara et al.   Acta Neuropathologica Communications

Glial Fibrillary Acidic Protein and Protein S-100B: Different Concentration Pattern of Glial Proteins in Cerebrospinal Fluid of Patients with Alzheimer's Disease and Creutzfeldt-Jakob Disease

(2017) Sarah Jesse et al.   JOURNAL OF ALZHEIMERS DISEASE

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid

(2016) Tobias Bittner et al.   Alzheimers & Dementia

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers

(2016) Marc Suárez‐Calvet et al.   EMBO Molecular Medicine

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Suspected non-Alzheimer disease pathophysiology — concept and controversy

(2016) Clifford R. Jack et al.   Nature Reviews Neurology

Plasma β-amyloid in Alzheimer’s disease and vascular disease

(2016) Shorena Janelidze et al.   Scientific Reports

The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

(2015) Ju-Hee Kang et al.   Alzheimers & Dementia

2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception

(2015) Michael W. Weiner et al.   Alzheimers & Dementia

Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study

(2015) Massimo S. Fiandaca et al.   Alzheimers & Dementia

Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration

(2015) Aiko Ishiki et al.   JOURNAL OF NEUROCHEMISTRY

Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease

(2015) Edward J. Goetzl et al.   NEUROLOGY

Tissue-based map of the human proteome

(2015) M. Uhlen et al.   SCIENCE

Amyloid biomarkers in Alzheimer's disease

(2015) Kaj Blennow et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease

(2015) Maartje I. Kester et al.   JAMA Neurology

Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease

(2015) Aline Dorey et al.   Frontiers in Neurology

Plasma phospholipids identify antecedent memory impairment in older adults

(2014) Mark Mapstone et al.   NATURE MEDICINE

CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease

(2013) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

Association of plasma and cortical amyloid beta is modulated by APOE ε4 status

(2013) Shanker Swaminathan et al.   Alzheimers & Dementia

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid

(2013) Susan M. Landau et al.   ANNALS OF NEUROLOGY

Heterophilic antibody interference in immunometric assays

(2013) Nils Bolstad et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid- 1-42 and   Proteins as Alzheimer Disease Biomarkers

(2013) J.-H. Kang et al.   CLINICAL CHEMISTRY

Circulating miR-125b as a biomarker of Alzheimer's disease

(2013) Lin Tan et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

A blood based 12-miRNA signature of Alzheimer disease patients

(2013) Petra Leidinger et al.   GENOME BIOLOGY

Clinical and multimodal biomarker correlates of ADNI neuropathological findings

(2013) Jon B Toledo et al.   Acta Neuropathologica Communications

Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer’s Disease Neuroimaging Initiative study patients

(2012) Michal J. Figurski et al.   Alzheimers & Dementia

Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium

(2012) Maria C. Carrillo et al.   Alzheimers & Dementia

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biofunctionalized Magnetic Nanoparticles for Specifically Detecting Biomarkers of Alzheimer’s Disease in Vitro

(2011) Che-Chuan Yang et al.   ACS Chemical Neuroscience

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Clifford R. Jack et al.   Alzheimers & Dementia

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Exosome-associated Tau Is Secreted in Tauopathy Models and Is Selectively Phosphorylated in Cerebrospinal Fluid in Early Alzheimer Disease

(2011) Sudad Saman et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Epidemiology of Alzheimer disease

(2011) Christiane Reitz et al.   Nature Reviews Neurology

YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease

(2010) Rebecca Craig-Schapiro et al.   BIOLOGICAL PSYCHIATRY

Tackling the widespread and critical impact of batch effects in high-throughput data

(2010) Jeffrey T. Leek et al.   NATURE REVIEWS GENETICS

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

(2009) Clifford R Jack et al.   LANCET NEUROLOGY

Inhibition of γ-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes

(2008) Robyn A. Sharples et al.   FASEB JOURNAL

Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship

(2008) Peter T. Nelson et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY